Innocare Pharma Ltd (9969.HK)
Company Info
Highlights
HK$21.79B
-HK$0.18
HK$253.91M
HK$218.06M
HK$4.22 - HK$10.96
HK$10.31
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Innocare Pharma Ltd (9969.HK) returned 58.46% year-to-date (YTD) and 86.65% over the past 12 months.
9969.HK
58.46%
22.00%
37.27%
86.65%
-8.01%
N/A
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of 9969.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -8.87% | 65.95% | -0.76% | 11.16% | -5.02% | 58.46% | |||||||
| 2024 | -22.79% | -3.01% | -9.88% | -0.43% | -6.70% | 11.57% | -3.53% | 7.10% | 35.34% | -1.93% | -1.66% | -6.31% | -11.61% |
| 2023 | -0.59% | -36.50% | -2.79% | 7.53% | -19.22% | -2.89% | 15.16% | -18.33% | -10.39% | 3.87% | 6.63% | 4.55% | -49.49% |
| 2022 | -24.97% | 7.67% | -1.13% | -9.82% | -4.36% | 26.94% | -17.34% | -1.45% | -26.97% | 15.20% | 15.81% | 28.44% | -10.85% |
| 2021 | 0.30% | 39.50% | -3.71% | 35.46% | -3.46% | 20.21% | -10.33% | -15.04% | -3.22% | -11.26% | 6.42% | -23.04% | 13.50% |
| 2020 | 16.00% | 25.83% | -2.65% | 5.45% | 2.04% | -15.33% | -20.47% | -1.98% | 29.29% | 5.31% | 37.41% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 91, 9969.HK is among the top 9% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Innocare Pharma Ltd (9969.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Innocare Pharma Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Innocare Pharma Ltd was 86.75%, occurring on Apr 19, 2024. The portfolio has not yet recovered.
The current Innocare Pharma Ltd drawdown is 68.52%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -86.75% | Jul 20, 2021 | 678 | Apr 19, 2024 | — | — | — |
| -39.24% | May 19, 2020 | 112 | Oct 29, 2020 | 67 | Feb 3, 2021 | 179 |
| -29.17% | Feb 17, 2021 | 15 | Mar 9, 2021 | 29 | Apr 22, 2021 | 44 |
| -20.31% | May 5, 2021 | 9 | May 17, 2021 | 18 | Jun 11, 2021 | 27 |
| -9.06% | Jun 16, 2021 | 3 | Jun 18, 2021 | 4 | Jun 24, 2021 | 7 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Innocare Pharma Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Innocare Pharma Ltd, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Innocare Pharma Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 9969.HK relative to other companies in the Biotechnology industry. Currently, 9969.HK has a P/S ratio of 21.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 9969.HK in comparison with other companies in the Biotechnology industry. Currently, 9969.HK has a P/B value of 2.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |